{"id":128567,"date":"2022-07-28T18:03:30","date_gmt":"2022-07-28T18:03:30","guid":{"rendered":"https:\/\/fin2me.com\/?p=128567"},"modified":"2022-07-28T18:03:30","modified_gmt":"2022-07-28T18:03:30","slug":"sources-roberts-fought-to-the-end-to-save-roe-v-wade","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/sources-roberts-fought-to-the-end-to-save-roe-v-wade\/","title":{"rendered":"Sources: Roberts fought to the end to save Roe v. Wade"},"content":{"rendered":"

New York (CNN Business)<\/cite>There’s a saying on Wall Street that traders often sell the news. Well, that hasn’t been the case with a tiny reproductive health company following the Supreme Court’s decision to overturn Roe v. Wade last month.<\/p>\n

Shares of Evofem Biosciences<\/span> (EVFM<\/span>)<\/span>, which makes a hormone-free contraceptive vaginal gel named Phexxi, have more than doubled since the court ruled that abortion rights are no longer federally protected by the Constitution, leaving it up to states to decide whether or not to ban abortions.
\nEvofem Biosciences had already been preparing for more interest in its products even before the ruling was official.<\/p>\n